Advertisement

Urologika

  • Bernd Mühlbauer
  • Hartmut Oßwald
Chapter

Zusammenfassung

Mit 70% der Verordnungen bleiben Prostatamittel die überwiegende Gruppe der Urologika. Urologische Spasmolytika repräsentieren weiterhin knapp 30 % des Verordnungsvolumens, während Urolithiasis- und Kathetermittel vernachlässigbare Verordnungszahlen erreichen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Alhasso AA, McKinlay J, Patrick K, Stewart L (2006) Anticholinergic drugs versus non-drug active therapies for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006; 4:CD00319–3Google Scholar
  2. Blake-James BT, Rashidian A, Ikeda Y, Emberton M (2007) The role of anticholinergics in men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a systematic review and meta-analysis. BJU Int 99:85–96PubMedCrossRefGoogle Scholar
  3. Boyle P, Gould AL, Roehrborn CG (1996) Prostate volume predicts outcome of treatment of benign prostatic hyperplasia with finasteride: meta-analysis of randomized clinical trials. Urology 48:398–405PubMedCrossRefGoogle Scholar
  4. Chapple CR (1996) Selective a1-adrenoceptor antagonists in benign prostatic hyperplasia: rationale and clinical experience. Eur Urol 29:129–144PubMedGoogle Scholar
  5. Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, Ridder A; YM-905 Study Group (2004): Randomized, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. Brit J Urol Int. 93: 303–310Google Scholar
  6. Chapple CR, Montorsi F, Tammela TL, Wirth M, Koldewijn E, Fernández Fernández E; European Silodosin Study Group (2011) Silodosin therapy for lower urinary tract symptoms in men with suspected benign prostatic hyperplasia: results of an international, randomized, double-blind, placebo- and active-controlled clinical trial performed in Europe. Eur Urol 59:342–352CrossRefGoogle Scholar
  7. Choo MS, Lee JZ, Lee JB, Kim YH, Jung HC, Lee KS, Kim JC, Seo JT, Paick JS, Kim HJ, Na YG, Lee JG (2008) Efficacy and safety of solifenacin succinate in Korean patients with overactive bladder: a randomised, prospective, double-blind, multicentre study. Int J Clin Pract 62:1675–1683PubMedCentralPubMedCrossRefGoogle Scholar
  8. Djavan B, Marberger M (1999): A meta-analysis on the efficacy and tolerability of alpha1-adrenoceptor antagonists in patients with lower urinary tract symptoms suggestive of benign prostatic obstruction. Eur Urol 36: 1–13Google Scholar
  9. European Medicines Agency (EMEA) (2004): Ausschuss für Humanarzneimittel. Europäischer Bewertungsbericht (EPAR) Emselex. Im Internet: http://www.emea.eu.int/humandocs/HUMANS/EPAR/emselex/ emselex.htmGoogle Scholar
  10. Flanigan RC, Reda DJ, Wasson JH, Anderson RJ, Abdellatif M, Bruskewitz RC (1998) 5-year outcome of surgical resection and watchful waiting for men with moderately symptomatic benign prostatic hyperplasia: a Department of Veterans Affairs cooperative study. J Urol 160:12–16PubMedCrossRefGoogle Scholar
  11. Grünewald V (2005): Pharmakologische Therapie von neurogenen Harnblasenfunktionsstörungen. In: Truß MC et al: Pharmakotherapie in der Urologie. Springer Medizin Heidelberg, S. pp 383–311Google Scholar
  12. Haab F, Stewart L, Dwyer P (2004) Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder. Eur Urol 45:420–429PubMedCrossRefGoogle Scholar
  13. Harvey M-A, Baker K, Wells GA (2003) Tolterodine versus oxybutynin in the treatment of urge urinary incontinence: A meta-analysis. Am J Obstet Gynecol 185:56–61CrossRefGoogle Scholar
  14. Hay-Smith J, Herbison P, Ellis G, Morris A (2005) Which anticholinergic drug for overactive bladder symptoms in adults. Cochrane Database Syst Rev 2005; 3:CD00542–9Google Scholar
  15. Kelleher CJ, Cardozo L, Chapple CR, Haab F, Ridder AM (2005) Improved quality of life in patients with overactive bladder symptoms treated with solifenacin. BJU Int 95:81–85PubMedCrossRefGoogle Scholar
  16. Kirby RS, Roehrborn C, Boyle P, Bartsch G, Jardin A, Cary MM, Sweeney M, Grossman EB and the Prospective European Doxazosin and Combination Therapy Study Investigators (2003) Efficacy and tolerability of doxazosin and finasteride, alone or in combination, in treatment of symptomatic benign prostatic hyperplasia: the Prospective European Doxazosin and Combination Therapy (PRE-DICT) trial. Urology 61:119–126PubMedCrossRefGoogle Scholar
  17. McConnell JD, Roehrborn CG, Bautista OM, Andriole GL Jr, Dixon CM, Kusek JW, Lepor H, McVary KT, Nyberg LM Jr, Clarke HS, Crawford ED, Diokno A, Foley JP, Foster HE, Jacobs SC, Kaplan SA, Kreder KJ, Lieber MM, Lucia MS, Miller GJ, Menon M, Milam DF, Ramsdell JW, Schenkman NS, Slawin KM, Smith JA; Medical Therapy of Prostatic Symptoms (MTOPS) Research Group (2003) The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. N Engl J Med 349:2387–2398PubMedCrossRefGoogle Scholar
  18. Milani S, Djavan B (2005) Lower urinary tract symptoms suggestive of benign prostatic hyperplasia: latest update on alpha-adrenoceptor antagonists. BJU Int 95(Suppl 4):29–36PubMedCrossRefGoogle Scholar
  19. Millard RJ, Moore K, Rencken R, Yalcin I, Bump RC; Duloxetine UI Study Group (2004): Duloxetine vs placebo in the treatment of stress urinary incontinence: a four-continent randomized clinical trial. Brit J Urol Int 93: 311–318Google Scholar
  20. Nabi G, Cody JD, Ellis G, Herbison P, Hay-Smith J (2006) Anticholinergic drugs versus placebo for overactive bladder syndrome in adults. Cochrane Database Syst Rev 2006; 4:CD00378–1Google Scholar
  21. Nickel JC, Gilling P, Tammela TL, Morrill B, Wilson TH, Rittmaster RS (2011) Comparison of dutasteride and finasteride for treating benign prostatic hyperplasia: the Enlarged Prostate International Comparator Study (EPICS). BJU Int 108:388–394PubMedCrossRefGoogle Scholar
  22. Roehrborn CG, Siami P, Barkin J, Damião R, Major-Walker K, Nandy I, Morrill BB, Gagnier RP, Montorsi F; CombAT Study Group (2010) The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study. Eur Urol 57:123–131CrossRefGoogle Scholar
  23. Roehrborn CG, Barkin J, Siami P, Tubaro A, Wilson TH, Morrill BB, Gagnier RP (2011) Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial. BJU Int 107:946–954PubMedCrossRefGoogle Scholar
  24. Thüroff JW, Chartier-Kastler E, Corcus J, Humke J, Jonas U, Palmtag H, Tanagho EA (1998) Medical treatment and medical side effects in urinary incontinence in the elderly. World J Urol 16(suppl):S48–S61PubMedCrossRefGoogle Scholar
  25. Tsujii T (2000) Comparison of prazosin, terazosin and tamsulosin in the treatment of symptomatic benign prostatic hyperplasia: a short-term open, randomized multicenter study. Int J Urol 7:199–205PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2014

Authors and Affiliations

  • Bernd Mühlbauer
    • 1
  • Hartmut Oßwald
    • 1
  1. 1.Institut für Klinische PharmakologieBremen

Personalised recommendations